Association of LDL Cholesterol and Inflammation With Cardiovascular Events and Mortality in Hemodialysis Patients With Type 2 Diabetes Mellitus

American Journal of Kidney Diseases

Volumn 54, Issue 5, 2009, Pages 902-911

  Krane, Vera ^a   Winkler, Karl ^b   Drechsler, Christiane ^a   Lilienthal, Jürgen ^c   März, Winfried ^d   Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c DATAMAP GmbH   (Germany)

^d SYNLAB ACADEMY   (Germany)

Author keywords

C reactive protein (CRP); cardiovascular events; diabetes; hemodialysis; Low density lipoprotein (LDL); mortality; outcome

Indexed keywords

ALBUMIN; ATORVASTATIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART DEATH; HEART INFARCTION; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; MALE; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STROKE; SUDDEN DEATH; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; MALE; PROSPECTIVE STUDIES; PYRROLES; RENAL DIALYSIS;

EID: 70350036044     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.06.029     Document Type: Article

References (25)

1. Ridker P.M., Glynn R.J., and Hennekens C.H. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
2. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
3. Krane V., Winkler K., Drechsler C., Lilienthal J., März W., and Wanner C. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74 (2008) 1461-1467
4. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291 (2004) 451-459
5. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
6. Wanner C., Krane V., Ruf G., Marz W., and Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 71 (1999) S222-S226
7. Wanner C., Krane V., Marz W., et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D Study): Demographic and baseline characteristics. Kidney Blood Press Res 27 (2004) 259-266
8. Krane V., Heinrich F., Meesmann M., et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol 4 (2009) 394-400
9. Nauck M., Winkler K., Marz W., and Wieland H. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 41 (1995) 1761-1767
10. Chen Z., Peto R., Collins R., MacMahon S., Lu J., and Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 303 (1991) 276-282
11. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
12. Chiang C.K., Ho T.I., Hsu S.P., et al. Low-density lipoprotein cholesterol: Association with mortality and hospitalization in hemodialysis patients. Blood Purif 23 (2005) 134-140
13. Coresh J., Longenecker J.C., Miller III E.R., Young H.J., and Klag M.J. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9 suppl 12 (1998) S24-S30
14. Iseki K., Yamazato M., Tozawa M., and Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61 (2002) 1887-1893
15. Lowrie E.G., and Lew N.L. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 (1990) 458-482
16. Gierens H., Nauck M., Roth M., et al. Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler Thromb Vasc Biol 20 (2000) 1777-1783
17. Amarenco P., Goldstein L.B., Callahan III A., et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 204 (2009) 515-520
18. Lewington S., Whitlock G., Clarke R., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007) 1829-1839
19. Patel A., Woodward M., Campbell D.J., et al. Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. Eur Heart J 26 (2005) 1910-1915
20. Iso H., Jacobs Jr. D.R., Wentworth D., Neaton J.D., and Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 320 (1989) 904-910
21. Lindenstrom E., Boysen G., and Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study. BMJ 309 (1994) 11-15
22. Horne B.D., Muhlestein J.B., Carlquist J.F., et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 36 (2000) 1774-1780
23. Kovesdy C.P., Anderson J.E., and Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: Effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 18 (2007) 304-311
24. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., and Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 (1997) 230-236
25. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 (2003) 1050-1065